Integrating research and development: The emergence of rational drug design in the pharmaceutical industry

Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences

Volumn 36, Issue 3, 2005, Pages 513-537

  Adam, Matthias ^a  

^a BIELEFELD UNIVERSITY   (Germany)

Author keywords

Biomedicine; Corporate research; Experiment; Interaction model; Pharmacology; Sir James Black

Indexed keywords

CAPTOPRIL; LOSARTAN; PROPRANOLOL;

ARTICLE; DRUG DESIGN; DRUG INDUSTRY; GERMANY; HUMAN; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; UNITED STATES;

BIOMEDICAL RESEARCH; CAPTOPRIL; DRUG DESIGN; DRUG INDUSTRY; GERMANY; HUMANS; LOSARTAN; PROPRANOLOL; UNITED STATES;

EID: 24144498743     PISSN: 13698486     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.shpsc.2005.07.003     Document Type: Article

References (61)

1. R.P. Ahlquist A study of the adrenotropic receptors American Journal of Physiology 153 1948 586-599
2. A.J. Ariens Affinity and intrinsic activity in the theory of competitive inhibition Archives internationales de pharmacodynamie et de thérapie 99 1954 32-49
3. J.W. Black The predictive value of animal tests in relation to drugs affecting the cardiovascular system in man In G. Wolstenholme & R. Porter (Eds.) Drug responses in man 1967 Churchill London pp 111-124
4. J.W. Black Ahlquist and the development of beta-adrenoreceptor antagonists Postgraduate Medical Journal 52 Suppl. 4 1976 11-13
5. J.W. Black Drugs from emasculated hormones: The principle of syntopic antagonism Science 245 1989 486-493
6. J.W. Black A personal view of pharmacology Annual Review of Pharmacology and Toxicology 36 1996 1-33
7. R. Brown J. Quirk & P. Kirkpatrick Eplerenone Nature Reviews Drug Discovery 2 2003 177-178
8. V. Bush Science: The endless frontier 1945 United States Government Printing Office Washington, D.C.
9. L.D. Byers & R. Wolfenden Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A Biochemistry 12 1973 2070-2078
10. W.B. Cannon & A. Rosenblueth Autonomic neuro-effector systems 1937 Macmillan London
11. A.T. Chiu W.F. Herblin D.E. McCall et al. Identification of angiotensin II receptor subtypes Biochemical and Biophysical Research Communications 165 1989 196-203
12. A.J. Clark General pharmacology repr. ed. 1970 Springer Berlin (First published 1937)
13. Cockburn, I. M., Henderson, R., & Stern, S. (1999). The diffusion of science driven drug discovery: Organizational change in pharmaceutical research. National Bureau of Economic Research Working Paper, 7359. http://www.nber.org/papers/w7359. (Last accessed 5 May 2004).
14. D.W. Cushman H.S. Cheung E.F. Sabo et al. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids Biochemistry 16 1977 5484-5491
15. D.W. Cushman H.S. Cheung E.F. Sabo et al. Angiotensin converting enzyme inhibitors: Evolution of a new class of antihypertensive drugs In Z.P. Horovitz (Ed.) Angiotensin converting enzyme inhibitors. Mechanisms of action and clinical implications 1981 Urban & Schwarzenberg Baltimore pp 3-25
16. D.W. Cushman H.S. Cheung E.F. Sabo et al. Development and design of specific inhibitors of angiotensin-converting enzyme American Journal of Cardiology 49 1982 1390-1394
17. D.W. Cushman & M.A. Ondetti History of the design of captopril and related inhibitors of angiotensin converting enzyme Hypertension 17 1991 589-592
18. D.W. Cushman J. Pluščec N.J. Williams Inhibition of angiotensin-converting enzyme by analogs of peptides from Bothrops jararaca venom Experientia 29 1973 1032-1035
19. H. Etzkowitz & L. Leydesdorff The endless transition: A 'triple helix' of university-industry-government relations Minerva 36 1998 203-208
20. S.H. Ferreira D.C. Bartelt & L.J. Greene Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom Biochemistry 9 1970 2583-2593
21. S.H. Ferreira L.J. Greene V.A. Alabaster Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme Nature 225 1970 379-380
22. S.H. Ferreira & M. Rocha e Silva Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom Experientia 21 1965 347-349
23. A.E. Fletcher & C.T. Dollery Side effects associated with inhibitors of angiotensin-converting enzyme In J.I. Robertson & M.G. Nicholls (Eds.) The renin-angiotensin system 1993 Mosby London pp 99.1-99.15
24. A. Gambardella Science and innovation. The US pharmaceutical industry during the 1980s 1995 Cambridge University Press Cambridge
25. M. Gibbons C. Limoges H. et al. Nowotny The new production of knowledge. The dynamics of science and research in contemporary societies 1994 Sage London
26. S. Glennan Rethinking mechanistic explanation Philosophy of Science 69 Suppl. 2002 S342-S353
27. A. Good S.R. Krystek & J.S. Mason High-throughput and virtual screening: Core lead discovery technologies move towards integration Drug Discovery Today 5 12, Suppl. 2000 S61-S69
28. J. Goodman Can it ever be pure science? Pharmaceuticals, the pharmaceutical industry and biomedical research in the twentieth century In J.-P. Gaudillière & I. Löwy (Eds.) The invisible industrialist 1998 Macmillan London pp 143-166
29. I. Hacking Representing and intervening 1983 Cambridge University Press Cambridge
30. J. Irvine & B.R. Martin Research foresight: Priority-setting in science 1989 Pinter London
31. C.I. Johnston Angiotensin-converting enzyme inhibitors In J.I. Robertson & M.G. Nicholls (Eds.) The renin-angiotensin system 1993 Mosby London pp 87.1-87.15
32. P. Keating & A. Cambrosio Biomedical platforms. Realigning the normal and the pathological in late-twentieth-century medicine 2003 MIT Press Cambridge, MA
33. P. Kitcher Science, truth, and democracy 2001 Oxford University Press Oxford
34. P. Larédo & P. Mustar The technoeconomic network: A socioeconomic approach to intervention in innovation In R. Coombs A. Richards P.P. Saviotti (Eds.) Technological innovation. The dynamics of cooperation in industrial innovation 1996 Elgar Cheltenham pp 143-164
35. J.E. Lesch Chemistry and biomedicine in an industrial setting: The invention of the sulfa drugs In S.H. Mauskopf (Ed.), Chemical sciences in the modern world 1993 University of Pennsylvania Press Philadelphia pp 158-215
36. R.A. Maxwell The state of the art of the science of drug discovery - an opinion Drug Development Research 4 1984 375-389
37. R.A. Maxwell & S.B. Eckhardt Drug discovery. A casebook and analysis 1990 Humana Clifton
38. M. Merlos X. Rabasseda & J.S. Silvestre Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies Methods and Findings in Experimental and Clinical Pharmacology 20 1998 805-815
39. M. Mizuno T. Sada M. Ikeda et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist European Journal of Pharmacology 285 1995 181-188
40. H.C. Moran & M.E. Perkins Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol Journal of Pharmacology and Experimental Therapeutics 124 1958 223-237
41. K.K.F. Ng & J.R. Vane Fate of angiotensin I in the circulation Nature 218 1968 144-150
42. M.G. Nicholls C.J. Charles I.G. et al. Crozier Blockade of the renin-angiotensin system Journal of Hypertension 12 Suppl. 10 1994 S95-S103
43. Nobel Assembly (1988). Press Release: The 1988 Nobel Prize in physiology or medicine. Nobel Assembly at the Karolinska Institute, http://www.nobel.se/medicine/laureates/1988/press.html. (Last accessed 5 May 2004).
44. M.A. Ondetti N. Williams E.F. Sabo et al. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis Biochemistry 10 1971 4033-4039
45. C.E. Powell & I.H. Slater Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol Journal of Pharmacology and Experimental Therapeutics 122 1958 480-488
46. F.A. Quiocho & W.N. Lipscomb Carboxypeptidase A: A protein and an enzyme Advances in Protein Chemistry 25 1971 1-78
47. Quirke, V. (2001). Black, James White. In Encyclopedia of Life Sciences. http://www.els.net. (Last accessed 5 May 2004).
48. W. Raab Myocardial metabolism in the pathogenesis and treatment of angina pectoris Cardiologia 22 1953 291-303
49. J.I. Robertson Renin and angiotensin: A historical review In J.I. Robertson & M.G. Nicholls (Eds.) The renin-angiotensin system 1993 Mosby London pp 1.1-1.18
50. N. Rosenberg Critical issues in science policy research Science and Public Policy 18 1991 335-346
51. R.G. Shanks The discovery of beta adrenoreceptor blocking drugs In M.J. Parnham & J. Bruinvels (Eds.), Discoveries in pharmacology Haemodynamics, hormones & inflammation Vol.2 1984 Elsevier Amsterdam pp 37-72
52. R.R. Smeby & S. Fermandjian Conformation of angiotensin II In B. Weinstein (Ed.), Chemistry and biochemistry of amino acids, peptides and proteins 1978 Marcel Dekker New York pp 117-162
53. C.G. Smith & J.R. Vane The Discovery of Captopril FASEB Journal 17 2003 788-789
54. M.P. Stapleton Sir James Black and propranolol Texas Heart Institute Journal 24 1997 336-342
55. R.P. Stephenson A modification of receptor theory British Journal of Pharmacology 11 1956 379-393
56. D.E. Stokes Pasteur's quadrant. Basic science and technological innovation 1997 Brookings Institution Press Washington, D.C.
57. P.B. Timmermans J.V. Duncia D.J. et al. Carini Discovery of losartan, the first angiotensin II receptor antagonist Journal of Human Hypertension 9 Suppl. 5 1995 S3-S18
58. R. Vos Drugs looking for diseases. Innovative drug research and the development of the beta blockers and the calcium antagonists 1991 Kluwer Dordrecht
59. V. Walsh Industrial R&D and its influence on the organization and management of the production of knowledge in the public sector In J.-P. Gaudillière I. Löwy (Eds.), The invisible industrialist 1998 Macmillan London pp 301-344
60. M. Weatherall In search of a cure. A history of pharmaceutical discovery 1990 Oxford University Press Oxford
61. White, S., Mele, M., Kamber, et al. (1989). Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochemical and Biophysical Research Communication, 163, 284-291.